Trade Biora Therapeutics Inc. - BIOR CFD

Add to favourite

0.6212

4.58%

View detailed chart

To be able to trade stocks like this, create an account and apply for a stock listing.

Create Account

Summary
Historical Data

Trading сonditions

Spread

0.0276

Long position overnight fee

-0.026179%

Short position overnight fee

0.003957%

Overnight fee time

21:00 (UTC)

Min traded quantity

0.01

Currency

USD

Margin

Stock exchange

United States of America

Commission on trade

Key Stats

Prev. Close	0.594
Open	0.6112
1-Year Change	-76.16%
Day's Range	0.6112 - 0.6412

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 23, 2024	0.6212	0.0239	4.00%	0.5973	0.6413	0.5973
Apr 22, 2024	0.5940	-0.0072	-1.20%	0.6012	0.6012	0.5762
Apr 19, 2024	0.6062	0.0150	2.54%	0.5912	0.6085	0.5812
Apr 18, 2024	0.5907	-0.0505	-7.88%	0.6412	0.6612	0.5712
Apr 17, 2024	0.6311	0.0099	1.59%	0.6212	0.6372	0.6112
Apr 16, 2024	0.6112	0.0106	1.76%	0.6006	0.6312	0.5912
Apr 15, 2024	0.6012	-0.0500	-7.68%	0.6512	0.6542	0.5912
Apr 12, 2024	0.6616	-0.0200	-2.93%	0.6816	0.6816	0.6512
Apr 11, 2024	0.6961	0.0145	2.13%	0.6816	0.6977	0.6713
Apr 10, 2024	0.6812	0.0000	0.00%	0.6812	0.6902	0.6613
Apr 9, 2024	0.6912	-0.0023	-0.33%	0.6935	0.7073	0.6737
Apr 8, 2024	0.7168	0.0056	0.79%	0.7112	0.7187	0.6912
Apr 5, 2024	0.7012	-0.0150	-2.09%	0.7162	0.7259	0.7011
Apr 4, 2024	0.7024	-0.0338	-4.59%	0.7362	0.7362	0.6763
Apr 3, 2024	0.7362	0.0150	2.08%	0.7212	0.7592	0.7212
Apr 2, 2024	0.7313	0.0001	0.01%	0.7312	0.7362	0.6915
Apr 1, 2024	0.7267	-0.0346	-4.54%	0.7613	0.8012	0.6612
Mar 28, 2024	1.0912	-0.0500	-4.38%	1.1412	1.1412	1.0712
Mar 27, 2024	1.1612	-0.0300	-2.52%	1.1912	1.2112	1.1512
Mar 26, 2024	1.2812	0.0400	3.22%	1.2412	1.3112	1.2112

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Biora Therapeutics Inc. Company profile

Progenity (PROG)/Biora Therapeutics (BIOR) is a biotechnology firm focused on the development of oral biotherapeutics. Founded in 2010, the company creates drug-device combinations that enable new therapeutic delivery methods in two main areas:

Targeted delivery of therapeutics to the site of disease in the gastrointestinal (GI) tract, to improve outcomes for patients with Inflammatory Bowel Disease (IBD)
Systemic biotherapeutic delivery, which is intended to replace injection with needle-free, oral delivery technology

Progenity is also working on diagnostic tools to help characterise the GI tract and diagnose GI diseases such as Small Intestine Bacterial Overgrowth (SIBO). The technologies can pinpoint the location of the disease.

Prior to June 2021, the San Diego, California-based company focused on the prenatal carrier screening and non-invasive prenatal test market. It targeted preconception planning and routine pregnancy management for genetic disease risk assessment.

The company’s operations included anatomic and molecular pathology testing products under an affiliate, Avero Diagnostics.

A former affiliate, Mattison Pathology, a Texas firm trading as Avero Diagnostics, expanded the company’s operations to include anatomic and molecular pathology testing products.

The company also operated a certified laboratory in Michigan that specialised in the molecular testing markets serving women’s health providers in the obstetric, gynaecological, fertility, and maternal foetal medicine speciality areas in the US.

In June 2021, Progenity announced a strategic transformation which included closing the Progenity genetics lab in Ann Arbor, Michigan. It sold the Avero laboratory business in December 2021 as part of the transformation.

On 12 April 2022, Progenity announced it would change its name to Biora Therapeuctics in the second quarter of 2022. The strategy aims to better reflect its focus of developing targeted and systemic oral delivery of biotherapeutics.

The company will also change its stock symbol on the Nasdaq from PROG to BIOR. Progenity went public on 19 June 2020.

Industry:

Bio Therapeutic Drugs

4330 La Jolla Village Drive
Suite 200
SAN DIEGO
CALIFORNIA 92122
US

News

We’re partnering with Newsquawk

Filter out the noise and focus on the news that matters.

08:32, 23 April 2024

US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft

The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.

15:56, 22 April 2024

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024